P&T COMMUNITY
 
MediMedia Managed Markets
Our
Other
Journal
Managed Care magazine
Login / Register
Join Us  Facebook  Twitter  Linked In

News Categories

 

 

 

Positive Phase III Data Reported for IBS Drug Eluxadoline

Response rates significantly higher versus placebo (February 4)

Eluxadoline (Furiex Pharmaceuticals) has met the primary endpoint of a composite response based on simultaneous improvements in stool consistency and abdominal pain in two phase III trials of patients with diarrhea-predominant irritable bowel syndrome (IBS-D).

The two studies (3001 and 3002) were randomized, double-blind, placebo-controlled trials in which a total of 2,428 patients received eluxadoline 75 mg twice daily (BID), eluxadoline 100 mg BID, or placebo BID. The primary efficacy endpoint was a composite response evaluated over the initial 12 weeks of double-blind treatment. Response rates were compared based on patients who met the daily composite response criteria (improvement in pain and stool consistency) for at least 50% of the days from weeks 1 to 12.

In study 3001, patients receiving eluxadoline demonstrated significantly higher responder rates for the composite endpoint (the patients' response over weeks 1 to 12). The rates were 25.1% for eluxadoline 100 mg (P = 0.004), 23.9% for eluxadoline 75 mg (P = 0.014), and 17.1% for placebo.

In study 3002, patients receiving eluxadoline also demonstrated significantly higher responder rates for the composite endpoint. The rates were 29.5% for eluxadoline 100 mg, 28.9% for eluxadoline 75 mg, and 16.2% for placebo (P < 0.001 for both doses).

Source: Furiex Pharmaceuticals; February 4, 2014.

More stories